XW033DA
Introduction Peripheral Vein to New Technology Group 10 with Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension, Percutaneous Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | X New Technology |
| Body System | W Anatomical Regions |
| Operation | 0 Introduction |
| Body Part | 3 Peripheral Vein |
| Approach | 3 Percutaneous |
| Device | D Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension |
| Qualifier | A New Technology Group 10 |
Operation Definition
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
Procedure Overview
This family covers putting a therapeutic, diagnostic, nutritional, or preventive substance into or onto a body region, using a product recently approved under the New Technology pathway rather than an established drug or agent. It is not tied to one organ system but to broader anatomical regions, which is used when the substance is delivered in a way that does not target a single specific body part.
Clinically, this might apply to a patient receiving a newly approved anti-infective, an engineered biologic, or another agent whose novelty is what earns it separate tracking, often because it addresses a resistant infection or a condition that standard substances do not adequately treat.
Anatomy & Axis Detail
Peripheral Vein
Peripheral veins are the superficial and deep venous vessels of the extremities and other non-central locations, commonly accessed for intravenous therapy because they are relatively easy to cannulate and carry lower procedural risk than central venous access. Introduction procedures coded here under New Technology involve infusing a novel substance through a peripheral vein into the systemic circulation, distinguishing this route from central venous administration where drug concentration, infusion rate, or vessel size requirements differ. Because peripheral veins have smaller caliber and lower flow rates than central vessels, certain New Technology agents may be formulated or dosed specifically for this route to minimize irritation or infiltration. Accurate coding depends on confirming that the access point was genuinely a peripheral rather than a central vein.
Approach: Percutaneous
In New Technology, Percutaneous describes entry into the body via needle or instrument puncture through the skin or a mucous membrane, without a surgical incision, mirroring the same concept in Medical and Surgical. It is distinguished from Open access, which requires a full incision, and from Percutaneous Endoscopic, which adds visualization through the puncture site.
Device / Substance / Technology: Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension
Donislecel-jujn is an allogeneic pancreatic islet cellular suspension derived from deceased donor pancreata, infused into the hepatic portal vein to restore insulin-producing capacity in patients with brittle type 1 diabetes and severe hypoglycemia unawareness. As a cell-replacement rather than pharmacologic or antibody-based therapy, it is distinct from every other agent in this list, functioning through direct engraftment of hormone-secreting tissue.
Qualifier: New Technology Group 10
New Technology Group 10 flags a procedure as part of the 2023 batch of add-on codes recognized under the New Technology section. The value itself carries no information about the device or drug involved; that comes from the table, body part, and approach values alongside it. Coders should not confuse it with Group 9 or Group 11, which cover the cohorts approved in the years immediately before and after.
Coding & Documentation
Coders need the medication administration record or physician note to name the specific substance given and confirm it is one recognized under the current New Technology list, since this family exists specifically to track these products separately from routine drug administration. The route and anatomical region also need to be clearly stated.
A common error is coding a routine medication administration under this family simply because it sounds unfamiliar, when in fact only substances formally approved under the New Technology pathway qualify. Another is missing the code entirely when a newly approved agent is documented only by a shorthand or trade name the coder does not recognize.
Commonly Confused With
This is frequently confused with standard Administration section codes used for everyday medications and fluids. The distinguishing factor is strictly whether the substance itself has New Technology approval, since the delivery method and clinical intent can look identical to a routine medication given for the same reason.